Qingdao NovelBeam Technology Co. Ltd. A Net Assets
Qingdao NovelBeam Technology Co. Ltd. A net assets. Based on the latest financial reports, Qingdao NovelBeam Technology Co. Ltd. A (688677) has net assets worth CN¥1.38 Billion CNY (≈ $202.09 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.63 Billion ≈ $237.83 Million USD) and total liabilities (CN¥244.22 Million ≈ $35.74 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Qingdao NovelBeam Technology Co. Ltd. A annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.38 Billion |
| % of Total Assets | 84.97% |
| Annual Growth Rate | 29.02% |
| 5-Year Change | 22.84% |
| 10-Year Change | 845.63% |
| Growth Volatility | 63.93 |
Net Assets of Qingdao NovelBeam Technology Co. Ltd. A (2013–2025)
Net assets of Qingdao NovelBeam Technology Co. Ltd. A from 2013 to 2025. This chart illustrates how Qingdao NovelBeam Technology Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See Qingdao NovelBeam Technology Co. Ltd. A net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Qingdao NovelBeam Technology Co. Ltd. A (2013–2025)
The table below shows the annual net assets of Qingdao NovelBeam Technology Co. Ltd. A from 2013 to 2025. For live market cap and overall valuation, see 688677 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.34 Billion ≈ $196.79 Million |
+3.01% |
| 2024-12-31 | CN¥1.31 Billion ≈ $191.03 Million |
+0.98% |
| 2023-12-31 | CN¥1.29 Billion ≈ $189.17 Million |
+5.75% |
| 2022-12-31 | CN¥1.22 Billion ≈ $178.89 Million |
+11.67% |
| 2021-12-31 | CN¥1.09 Billion ≈ $160.20 Million |
+242.44% |
| 2020-12-31 | CN¥319.69 Million ≈ $46.78 Million |
+42.21% |
| 2019-12-31 | CN¥224.80 Million ≈ $32.90 Million |
-2.03% |
| 2018-12-31 | CN¥229.45 Million ≈ $33.58 Million |
+18.47% |
| 2017-12-31 | CN¥193.68 Million ≈ $28.34 Million |
+36.19% |
| 2016-12-31 | CN¥142.21 Million ≈ $20.81 Million |
+50.06% |
| 2015-12-31 | CN¥94.77 Million ≈ $13.87 Million |
+36.09% |
| 2014-12-31 | CN¥69.64 Million ≈ $10.19 Million |
+10.20% |
| 2013-12-31 | CN¥63.19 Million ≈ $9.25 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Qingdao NovelBeam Technology Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3662.0% over the analyzed period, indicating profitable operations and earnings retention.
Qingdao NovelBeam Technology Co. Ltd. A Net Assets Breakdown (December 2025)
Qingdao NovelBeam Technology Co. Ltd. A net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥670.29 Million | 49.76% |
| Other Components | CN¥676.75 Million | 50.24% |
| Total Equity | CN¥1.35 Billion | 100.00% |
Qingdao NovelBeam Technology Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Qingdao NovelBeam Technology Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TeamViewer AG
F:TMV
|
$857.02 Million |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR
|
$857.36 Million |
|
Camden National Corporation
NASDAQ:CAC
|
$857.91 Million |
|
Ryerson Holding Corp
NYSE:RYI
|
$858.13 Million |
|
Cryoport Inc
NASDAQ:CYRX
|
$855.97 Million |
|
Daxin Materials Corp
TW:5234
|
$855.95 Million |
|
Guangxi Radio and Television Information Network Corp Ltd
SHG:600936
|
$855.83 Million |
|
AB SKF (publ)
ST:SKF-A
|
$855.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Qingdao NovelBeam Technology Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,303,492,801 to 1,347,040,388, a change of 43,547,587 (3.3%).
- Net income of 171,603,500 contributed positively to equity growth.
- Dividend payments of 74,087,035 reduced retained earnings.
- Other comprehensive income decreased equity by 3,149,027.
- Other factors decreased equity by 50,819,851.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥171.60 Million | +12.74% |
| Dividends Paid | CN¥74.09 Million | -5.5% |
| Other Comprehensive Income | CN¥-3.15 Million | -0.23% |
| Other Changes | CN¥-50.82 Million | -3.77% |
| Total Change | CN¥- | 3.34% |
Book Value vs Market Value Analysis
This analysis compares Qingdao NovelBeam Technology Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.32x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 24.39x to 4.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥2.00 | CN¥48.80 | x |
| 2014-12-31 | CN¥2.21 | CN¥48.80 | x |
| 2015-12-31 | CN¥2.93 | CN¥48.80 | x |
| 2016-12-31 | CN¥4.30 | CN¥48.80 | x |
| 2017-12-31 | CN¥2.03 | CN¥48.80 | x |
| 2018-12-31 | CN¥2.32 | CN¥48.80 | x |
| 2019-12-31 | CN¥2.36 | CN¥48.80 | x |
| 2020-12-31 | CN¥3.46 | CN¥48.80 | x |
| 2021-12-31 | CN¥9.33 | CN¥48.80 | x |
| 2022-12-31 | CN¥10.02 | CN¥48.80 | x |
| 2023-12-31 | CN¥10.64 | CN¥48.80 | x |
| 2024-12-31 | CN¥10.79 | CN¥48.80 | x |
| 2025-12-31 | CN¥11.30 | CN¥48.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Qingdao NovelBeam Technology Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.74%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.48%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.21x
- Recent ROE (12.74%) is below the historical average (17.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -1.48% | -1.79% | 0.36x | 2.31x | CN¥-7.24 Million |
| 2014 | 9.50% | 9.74% | 0.41x | 2.37x | CN¥-349.37K |
| 2015 | 16.40% | 21.08% | 0.39x | 1.98x | CN¥6.06 Million |
| 2016 | 23.04% | 23.49% | 0.66x | 1.49x | CN¥18.55 Million |
| 2017 | 26.33% | 28.22% | 0.78x | 1.19x | CN¥31.68 Million |
| 2018 | 24.36% | 27.18% | 0.74x | 1.22x | CN¥32.16 Million |
| 2019 | 32.67% | 28.45% | 0.77x | 1.50x | CN¥49.92 Million |
| 2020 | 30.55% | 35.01% | 0.66x | 1.32x | CN¥64.81 Million |
| 2021 | 10.79% | 38.02% | 0.26x | 1.08x | CN¥8.63 Million |
| 2022 | 14.97% | 38.29% | 0.34x | 1.14x | CN¥60.65 Million |
| 2023 | 11.27% | 30.96% | 0.34x | 1.08x | CN¥16.45 Million |
| 2024 | 10.38% | 30.56% | 0.30x | 1.12x | CN¥5.00 Million |
| 2025 | 12.74% | 28.48% | 0.37x | 1.21x | CN¥36.90 Million |
Industry Comparison
This section compares Qingdao NovelBeam Technology Co. Ltd. A's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,299,958,491
- Average return on equity (ROE) among peers: 2.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Qingdao NovelBeam Technology Co. Ltd. A (688677) | CN¥1.38 Billion | -1.48% | 0.18x | $856.04 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $911.32 Million | 9.77% | 4.17x | $411.07 Million |
| Blue Sail Medical Co Ltd (002382) | $9.80 Billion | -4.55% | 0.71x | $797.66 Million |
| Andon Health Co Ltd (002432) | $779.96 Million | 3.04% | 0.05x | $3.83 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $994.18 Million | 15.79% | 0.86x | $758.94 Million |
| Guangzhou Improve Med Instrument (300030) | $963.72 Million | 1.16% | 0.81x | $330.73 Million |
| QITIAN Technology Group Co Ltd (300061) | $1.16 Billion | -31.55% | 0.49x | $669.23 Million |
| Shanghai Tofflon Science Tech (300171) | $2.23 Billion | 10.48% | 0.44x | $1.53 Billion |
| Truking Technology Ltd (300358) | $4.32 Billion | -10.48% | 2.08x | $964.79 Million |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $1.55 Billion | 16.90% | 0.56x | $710.50 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $290.70 Million | 15.03% | 0.44x | $1.21 Billion |
About Qingdao NovelBeam Technology Co. Ltd. A
Qingdao NovelBeam Technology Co.,Ltd. engages in the research, development, production, and sales of medical endoscopic instruments and optical products worldwide. The company offers medical device products and components, such as endoscopes, light sources, and camera systems for surgical operations, as well as surgical external vision system, endoscope system, and other complete systems; and opt… Read more